Equity Overview
Price & Market Data
Price: $19.76
Daily Change: -$0.64 / 3.24%
Range: $19.51 - $21.34
Market Cap: $281,819,104
Volume: 112,580
Performance Metrics
1 Week: -9.48%
1 Month: 29.83%
3 Months: 18.32%
6 Months: -16.62%
1 Year: -46.85%
YTD: -13.56%
Company Details
Employees: 107
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.